Last reviewed · How we verify
Digestive Care, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PANCRECARB® (pancrelipase) | PANCRECARB® (pancrelipase) | phase 3 | Pancreatic enzyme replacement therapy | Gastroenterology |
Therapeutic area mix
- Gastroenterology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Abbott · 1 shared drug class
- Asian Institute of Gastroenterology, India · 1 shared drug class
- Foundation for Liver Research · 1 shared drug class
- Hospital Clinico Universitario de Santiago · 1 shared drug class
- Ohio State University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Digestive Care, Inc.:
- Digestive Care, Inc. pipeline updates — RSS
- Digestive Care, Inc. pipeline updates — Atom
- Digestive Care, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Digestive Care, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/digestive-care-inc. Accessed 2026-05-18.